Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer
Ella Day | August 1, 2025 | News story | Medical Communications, Research and Development | Oncology, Ryvu Therapeutics, colorectal cancer
Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific Reports. The study reveals a promising synergistic effect between mTOR and AKT inhibitors in colorectal cancer (CRC), highlighting the potential of this drug combination as a new therapeutic strategy.
The research is based on high-throughput screening of over 4,200 compounds using patient-derived primary CRC cell cultures – models that more closely replicate the complexity and heterogeneity of human tumours than traditional immortalised cell lines. Ryvu identified 33 compounds with selective activity against cancer cells while sparing healthy epithelial cells.
The combination of everolimus (which blocks mTOR) and uprosertib (which blocks AKT) demonstrated significant synergy, suggesting improved efficacy. This finding may have been missed using conventional screening methods, reinforcing the advantage of patient-derived systems.
The ONCO Prime platform also integrates artificial intelligence (AI) to enhance screening precision and efficiency, enabling scalable discovery of druggable targets across tumour types. It is designed to support the development of more personalised and effective cancer treatments.
“This publication validates our ONCO Prime approach, which combines advanced modelling with AI to identify meaningful therapeutic opportunities,” said Krzysztof Brzozka, chief scientific officer at Ryvu. “Our findings underscore the broader potential of the platform.”
Ella Day
1/8/25
Related Content
Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer
Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the …
Dual immunotherapy for bowel cancer now available under NHS
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in …
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with advanced non-small cell lung cancer NSCLC) with a BRAFV600E mutation
Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee …
